Active Ingredient(s): Enfortumab Vedotin-ejfv
FDA Approved: * December 18, 2019
Pharm Company: * ASTELLAS
Category: Cancer

Enfortumab vedotin,[2] sold under the brand name Padcev, is an antibody-drug conjugate[3] designed for the treatment of cancer expressing Nectin-4.[4] Enfortumab refers to the monoclonal antibody part, and vedotin refers to the payload drug (MMAE) and the linker. The most common side effects are fatigue, peripheral neuropathy (nerve damage resulting in tingling or numbness), decreased appetite, rash, alopecia (hair loss), nausea, altered taste, ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.